Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSP3-CRM-Vac4All dose-finding in healthy adults
NCT05197751Phase 1Unknown
- Sponsor
- Vac4All
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of MSP3-CRM-Vac4All in Malaria (3 cohorts), sponsored by Vac4All. Primary endpoints: Frequency and grade of solicited local and systemic reactions, Frequency and grade of unsolicited adverse events and 1 more. Status: unknown.
02
Drugs
MSP3-CRM-Vac4All
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT05197751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197751.